LV Mass Index Calculator

About the LV Mass Index Calculator

The LV Mass Index (LVMI) quantifies left ventricular hypertrophy by indexing LV mass to body surface area. Using the ASE-recommended Devereux formula, LV mass is calculated from three echocardiographic measurements: interventricular septal thickness (IVSd), LV internal diameter (LVIDd), and posterior wall thickness (PWTd), all measured at end-diastole.

LV hypertrophy is a major independent risk factor for cardiovascular morbidity and mortality, associated with increased risk of heart failure, arrhythmias, sudden cardiac death, and stroke. Importantly, LV hypertrophy is potentially reversible with blood pressure control, making serial LVMI measurement clinically valuable for monitoring treatment response.

Combining LVMI with relative wall thickness (RWT) enables classification into four LV geometry patterns: normal, concentric remodeling, eccentric hypertrophy, and concentric hypertrophy — each with distinct clinical associations and prognostic implications. This helps clinicians move from raw echo dimensions to a more usable summary of remodeling pattern and severity.

When This Page Helps

LVMI provides objective, quantitative assessment of LV size for monitoring hypertensive heart disease, valvular heart disease, athletic heart, and hypertrophic cardiomyopathy. It is more reliable than qualitative visual assessment and enables serial comparison over time.

The geometry classification adds clinical value by distinguishing pressure-overload patterns (concentric) from volume-overload patterns (eccentric), guiding both diagnosis and treatment priorities.

How to Use the Inputs

1. Select patient sex for sex-specific reference ranges.
2. Enter height and weight for BSA calculation.
3. Enter echocardiographic measurements from parasternal long-axis view.
4. IVSd, LVIDd, and PWTd should be measured at end-diastole.
5. Review LVMI severity classification and LV geometry pattern.
6. Compare with prior studies if available for longitudinal trending.

Example Calculation

Tips & Best Practices

• Measure all dimensions at end-diastole from the parasternal long-axis view.
• Leading-edge to leading-edge convention is used for ASE measurements.
• Use height-indexed LVMI (mass/height^2.7) for obese patients (BMI >30).
• RWT should be calculated to determine geometry pattern alongside LVMI.
• Echo-derived LV mass overestimates CMR-derived mass by approximately 10-20%.
• Serial LVMI trending is most reliable when the same sonographer and technique are used.

Clinical Significance of LV Geometry

The Framingham Heart Study demonstrated that LV geometry, not just mass alone, predicts outcomes. Concentric hypertrophy carries the highest cardiovascular risk, followed by eccentric hypertrophy, concentric remodeling, and normal geometry. Each pattern has a distinct pathophysiology and treatment consideration.

Indexing Dilemmas

BSA indexing is problematic in obesity because fat mass increases BSA without increasing cardiac demand proportional to lean body mass. Height-indexed LVMI (mass/height^2.7) eliminates this confound and is endorsed by ASE guidelines for obese patients. In extreme obesity, absolute LV mass without indexing may be most informative.

Advanced LV Mass Assessment

Cardiac MRI is the gold standard for LV mass quantification, with excellent accuracy and reproducibility. 3D echocardiography also improves accuracy over M-mode. Speckle tracking strain analysis provides additional information about myocardial mechanics beyond simple mass measurement.

Frequently Asked Questions

• What is the difference between LVMI indexed to BSA vs height?

  BSA-indexed LVMI is the standard, but it underestimates LVH in obese patients because BSA increases with body weight. Height-indexed LVMI (mass/height^2.7) is preferred for obese patients as it better detects true hypertrophy. Cutoffs are 49.2 g/m^2.7 for men and 46.7 g/m^2.7 for women.

• Can LV hypertrophy regress?

  Yes. Blood pressure control, weight loss, and treatment of valvular disease can produce significant LVH regression. ACE inhibitors and ARBs appear to cause the most regression per mmHg blood pressure reduction. Regression of LVH is associated with reduced cardiovascular events independent of blood pressure levels.

• How does athlete's heart differ from pathological LVH?

  Athlete’s heart typically shows mild eccentric hypertrophy (LVMI 95-115 in men) with normal diastolic function, a dilated LV cavity, and symmetric wall thickness. Red flags for pathological LVH: LVMI >130, RWT > 0.42, impaired relaxation, asymmetric hypertrophy, family history of sudden death, or abnormal ECG patterns.

• What causes concentric vs eccentric hypertrophy?

  Concentric hypertrophy (thick walls, normal cavity) results from pressure overload: chronic hypertension, aortic stenosis. Eccentric hypertrophy (normal walls, dilated cavity) results from volume overload: mitral/aortic regurgitation, obesity, high-output states. Concentric remodeling is an intermediate pattern often seen in early hypertension.

• How reproducible are m-mode LV mass measurements?

  M-mode LV mass has reasonable reproducibility (coefficient of variation ~15-18%) in good-quality studies, but can be inaccurate with off-axis measurements, LV regional wall motion abnormalities, or asymmetric hypertrophy. 3D-echo and cardiac MRI provide more accurate LV mass measurement with lower variability.

• What ECG criteria correlate with LVH?

  The Sokolow-Lyon criteria (SV1 + RV5 or RV6 >35mm) and Cornell criteria (SV3 + RaVL >28mm men, >20mm women) are ECG markers of LVH, but their sensitivity is only 20-60%. ECG LVH with strain pattern (ST depression + T-wave inversion in lateral leads) carries worse prognosis than voltage-only criteria.